Shares of Ariad Pharmaceuticals Inc. (ARIA) are up more than 5% in pre-market trading after the company this morning announced that Health Canada has approved the use of Iclusig in Canada for the treatment of adult patients with all phases of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom […]
View the full post at: Ariad (ARIA) Shares Up 5% Following Approval of Iclusig in Canada